Avaliação da alta precoce após transplante alogênico de medula óssea para leucemia mielóide crônica
Palavras-chave:
Leucemia mielóide crônica, Transplante de medula óssea, Estudos retrospectivos, Assistência ambulatorial, Tempo de internaçãoResumo
CONTEXTO E OBJETIVO: O número crescente de pacientes com indicação de transplante de medula óssea levou à implantação da alta hospitalar precoce em nosso serviço, com o intuito de reduzir o intervalo entre o diagnóstico e o transplante. Neste trabalho, avaliamos os resultados da alta precoce, com acompanhamento ambulatorial dos pacientes submetidos ao transplante de medula óssea alogênico portadores de leucemia mielóide crônica. TIPO E ESTUDO E LOCAL: Estudo retrospectivo, realizado no Serviço de Transplante de Medula Óssea do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. MÉTODOS: Foram avaliados os resultados do transplante de medula óssea alogênico, de doadores aparentados, até o dia 100 pós-transplante, de 51 pacientes portadores de leucemia mielóide crônica que receberam alta precoce, antes da pega medular. Os resultados foram comparados com o controle histórico constituído por 49 pacientes que receberam alta somente após a pega medular. RESULTADOS: Houve significativamente menos dias de hospitalização (p = 0,004), culturas positivas para Pseudomonas sp. (p = 0,006) e náusea e vômitos graus 2-3 (p < 0,001) no grupo de alta precoce. Não houve diferença significativa entre os grupos quanto à mortalidade e não ocorreu nenhum óbito até o dia 48 pós-transplante no grupo de alta precoce. CONCLUSÕES: O programa de alta precoce permitiu aumento do número de transplantes em leucemia mielóide crônica e outras doenças em nosso serviço, com redução do número de dias de internação hospitalar sem aumento da morbidade ou da mortalidade.
Downloads
Referências
Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;98(7):2039-42.
O’Dwyer ME. Chronic myelogenous leukemia. Curr Opin Oncol. 2003;15(1):10-5.
Maziarz RT, Mauro MJ. Transplantation for chronic myelog- enous leukemia: yes, no, maybe so... An Oregon perspective. Bone Marrow Transplant. 2003;32(5):459-69.
Peters WP, Ross M, Vredenburgh JJ, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol. 1994;21(4 Suppl 7):25-31.
Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost- effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20(6):445-50.
Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin’s lymphoma: results from the University of Ne- braska Medical Center 1989 to 1995. Bone Marrow Transplant. 1999;24(6):679-84.
Mishra V, Vaaler S, Brinch L. Cost analysis of autologous pe- ripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol. 2003;25(3):179-84.
Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 1998;21(9):927-32.
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hema- tologic malignancies: cost saving or cost shifting? J Clin Oncol. 1999;17(9):2811-8.
Westermann AM, Holtkamp MM, Linthorst GA, et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non- hematological malignancies. Ann Oncol. 1999;10(5):511-7.
Gonzalez-Ryan L, Haut PR, Coyne K, et al. Developing a pediatric outpatient transplantation program. The Children’s Memorial Hospital experience. Front Biosci. 2001;6:G1-5.
Frey P, Stinson T, Siston A, et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant. 2002;30(11):741-8.
Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology (Williston Park). 2000;14(2):171-85; discussion 185-6, 191-2.
Russell JA, Chaudhry A, Booth K, et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelod- ysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant. 2000;6(2):109-14.
Ruiz-Arguelles GJ, Gomez-Almaguer D, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OG, Jaime-Perez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol. 2001;66(4):241-4.
Svahn BM, Bjurman B, Myrback KE, Aschan J, Ringden O. Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant. 2000;26(10):1057-60.
Svahn BM, Remberger M, Myrback KE, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100(13):4317-24.
Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-92.
Lawrence CC, Gilbert CJ, Peters WP. Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann Pharmacother. 1996;30(9):941-5.
Summers N, Dawe U, Stewart DA. A comparison of in- patient and outpatient ASCT. Bone Marrow Transplant. 2000;26(4):389-95.
Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Mar- row Transplant. 2005;36(6):511-6.
Herrmann RP, Trent M, Cooney J, Cannell PK. Infections in patients managed at home during autologous stem cell trans- plantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 1999;24(11):1213-7.
Egerer G, Goldschmidt H, Salwender H, et al. Efficacy of continu- ous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15(2):119-23.
Seropian S, Nadkarni R, Jillella AP, et al. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and periph- eral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant. 1999;23(6):599-605.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
